These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30230137)

  • 41. Factors Associated with Dysfunctional Breathing in Patients with Difficult to Treat Asthma.
    Denton E; Bondarenko J; Tay T; Lee J; Radhakrishna N; Hore-Lacy F; Martin C; Hoy R; O'Hehir R; Dabscheck E; Hew M
    J Allergy Clin Immunol Pract; 2019; 7(5):1471-1476. PubMed ID: 30529061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical characteristics of patients with not well-controlled severe asthma in Japan: Analysis of the Keio Severe Asthma Research Program in Japanese population (KEIO-SARP) registry.
    Tanosaki T; Kabata H; Matsusaka M; Miyata J; Masaki K; Mochimaru T; Okuzumi S; Kuwae M; Watanabe R; Suzuki Y; Sayama K; Izuhara K; Asano K; Fukunaga K
    Allergol Int; 2021 Jan; 70(1):61-67. PubMed ID: 32651123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Severe exacerbations predict excess lung function decline in asthma.
    Bai TR; Vonk JM; Postma DS; Boezen HM
    Eur Respir J; 2007 Sep; 30(3):452-6. PubMed ID: 17537763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatable Traits That Predict Health Status and Treatment Response in Airway Disease.
    Hiles SA; Gibson PG; Agusti A; McDonald VM
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1255-1264.e2. PubMed ID: 33039647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Prevalence, Characteristics, and Patient Burden of Severe Asthma Determined by Using a Japan Health Care Claims Database.
    Sato K; Ohno T; Ishii T; Ito C; Kaise T
    Clin Ther; 2019 Nov; 41(11):2239-2251. PubMed ID: 31629532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
    Patel M; Pilcher J; Reddel HK; Qi V; Mackey B; Tranquilino T; Shaw D; Black P; Weatherall M; Beasley R;
    J Allergy Clin Immunol Pract; 2014; 2(6):751-8. PubMed ID: 25439367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Japanese guidelines for adult asthma 2017.
    Ichinose M; Sugiura H; Nagase H; Yamaguchi M; Inoue H; Sagara H; Tamaoki J; Tohda Y; Munakata M; Yamauchi K; Ohta K;
    Allergol Int; 2017 Apr; 66(2):163-189. PubMed ID: 28196638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current opinions for the management of asthma associated with ear, nose and throat comorbidities.
    Tiotiu A; Plavec D; Novakova S; Mihaicuta S; Novakova P; Labor M; Bikov A
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30463872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data.
    O'Connor RD; Bleecker ER; Long A; Tashkin D; Peters S; Klingman D; Gutierrez B
    J Asthma; 2010 May; 47(4):422-8. PubMed ID: 20528597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma.
    Semprini R; Williams M; Semprini A; McDouall A; Fingleton J; Holweg C; Weatherall M; Beasley R; Braithwaite I
    J Allergy Clin Immunol Pract; 2018; 6(6):1982-1988.e1. PubMed ID: 29609049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Precision medicine and treatable traits in chronic airway diseases - where do we stand?
    Ulrik CS; Vijverberg S; Hanania NA; Diamant Z
    Curr Opin Pulm Med; 2020 Jan; 26(1):33-39. PubMed ID: 31644440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils.
    Walsh CJ; Zaihra T; Benedetti A; Fugère C; Olivenstein R; Lemière C; Hamid Q; Martin JG
    Clin Exp Allergy; 2016 Oct; 46(10):1291-302. PubMed ID: 27214328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients.
    Jeong SH; Lee H; Carriere KC; Shin SH; Moon SM; Jeong BH; Koh WJ; Park HY
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1857-65. PubMed ID: 27536097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.
    Polverino E; Dimakou K; Hurst J; Martinez-Garcia MA; Miravitlles M; Paggiaro P; Shteinberg M; Aliberti S; Chalmers JD
    Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30049739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.
    Papi A; Mansur AH; Pertseva T; Kaiser K; McIver T; Grothe B; Dissanayake S
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):346-61. PubMed ID: 27104231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum Magnesium and Vitamin D Levels as Indicators of Asthma Severity.
    Shaikh MN; Malapati BR; Gokani R; Patel B; Chatriwala M
    Pulm Med; 2016; 2016():1643717. PubMed ID: 27818797
    [No Abstract]   [Full Text] [Related]  

  • 58. Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma.
    Westerhof GA; de Groot JC; Amelink M; de Nijs SB; Ten Brinke A; Weersink EJ; Bel EH
    Respir Med; 2016 Sep; 118():122-127. PubMed ID: 27578481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.
    Fuhlbrigge AL; Bengtsson T; Peterson S; Jauhiainen A; Eriksson G; Da Silva CA; Johnson A; Sethi T; Locantore N; Tal-Singer R; Fagerås M
    Lancet Respir Med; 2017 Jul; 5(7):577-590. PubMed ID: 28583396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function.
    Mansur AH; Srivastava S; Sahal A
    Respir Med; 2018 Oct; 143():31-38. PubMed ID: 30261989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.